Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06298630
Recruiting Observational

Long-term Follow-up Study of BRL-101 for TDT

NCT06298630 · tracked via the Priya Life Science China tracker
Sponsor
Bioray Laboratories
Phase
Observational
Started
2024-12-08
Last updated
2026-07-21

Condition(s) studied

Thalassemia, Beta

Investigational drug(s) / intervention(s)

Assessments

Assessments: Safety and efficacy assessments

Study summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Eligibility

Sex
ALL
Min age
3 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) 2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia. Exclusion Criteria: \- There are no exclusion criteria for this study

Primary outcome measure(s)

  • Incidence of hematologic malignancies — Up to 15 years post-drug product infusion
    Such as new lymphoma, leukemia, MDS, etc.
  • Frequency, grade, and relationship of SAEs — Within 2 years to 5years after BRL-101 Infusion
    Frequency, grade, and relationship to BRL-101 of SAEs following BRL-101 reinfusion.

Trial sites (7)

FacilityCityRegionStatus
Nanfang Hospital, Southern Medical University Guangzhou Guangdong Active Not Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou Guangdong Not Yet Recruiting
Shenzhen Children 's Hospital Shenzhen Guangdong Not Yet Recruiting
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital Nanning Guangxi Not Yet Recruiting
Xiangya Hospital of Central South University Changsha Hunan Recruiting
Tianjin Institute of Hematology Tianjin Tianjin Municipality Recruiting
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY Guangxi China Recruiting

More Bioray Laboratories trials in China

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases Enrolling by invitation
Universal CAR-T Cell Therapy for MM Recruiting
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia Active, not recruiting
Long-term Follow-up Study of BHC001 for TDT Recruiting
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma Recruiting

Other trials for the same condition

Long-term Follow-up Study of BHC001 for TDT Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06298630 on ClinicalTrials.gov ↗ ← All trials in China